Open AccessTocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
Author(s) -
Khatib Mohamad Y.,
Shaik Karimulla S.,
Ahmed Amna A.,
Alwraidat Mohammad A.,
Mohamed Ahmed S.,
Abou Kamar Mohamad R.,
Sharaf Eldean Mouhammad Z.,
Aldaraiseh Bashar K.,
Nashwan Abdulqadir J.
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3487
Subject(s) - medicine , tocilizumab , covid-19 , cytomegalovirus , perforation , colitis , bowel perforation , cytomegalovirus infections , gastroenterology , intensive care medicine , surgery , immunology , virology , complication , human immunodeficiency virus (hiv) , virus , viral disease , human cytomegalovirus , herpesviridae , punching , materials science , disease , infectious disease (medical specialty) , metallurgy , outbreak
The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life‐threatening bleeding and mortality.